Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide

What Was Tested

Researchers studied Goserelin and Degarelix in this randomized controlled trial publication.

The treatment of intermediate- to high-risk prostate cancer with radical radiotherapy is usually in combination with neoadjuvant androgen deprivation therapy.

Who Took Part

The abstract describes 244 men taking part.

The age groups tagged for this paper are older adults, men only.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.

Nothing was hidden in this open-label Goserelin study: the men and staff both knew the treatment.

Groups ran in parallel: each of the men stayed in one arm throughout.

The severity and relief of lower urinary tract symptoms were assessed by the International Prostate Symptom Score questionnaire.

Quality of life was assessed by the eighth question of the International Prostate Symptom Score.

What Was Measured

Topics PubMed links to this paper include Androgen Antagonists, Anilides, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Goserelin, Kallikreins and Neoadjuvant Therapy.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Goserelin and Degarelix in 244 men.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Clinical oncology (Royal College of Radiologists (Great Britain))), a journal based in England.

More context: the Goserelin compound page and the Degarelix compound page, all human trials.